BASEL (dpa-AFX) - Novartis (NVS) announced a new analysis from the phase III
FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of
Gilenya or fingolimod. The analysis evaluated the proportion of Gilenya patients
WESTON (dpa-AFX) - Biogen (BIIB) announced it will present new data that
reinforce the efficacy and safety profile of TECFIDERA (dimethyl fumarate) in a
broad range of people with relapsing-remitting multiple sclerosis. The company
said the new...
Roche's experimental therapy, ocrelizumab, recently posted positive Phase III data in patients with primary progressive multiple sclerosis, a less common form of the disease--affecting about 10% to 20% of sufferers--that right now remains untreated.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today
the approval by the Japanese Ministry of Health, Labour and Welfare
(MHLW) of once-daily COPAXONE® (glatiramer acetate injection)
20mg injection for the...
India Globalization Capital, Inc. (IGC) announces that the company applied for a provisional patent based on a novel therapy that uses cannabinoid extracts from the cannabis plant for the treatment of cachexia.
Cachexia is a condition that...
Oops! Unable to complete your request. Please refresh your browser.